Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary.
Authors
Singh, SCarnaghi, C
Buzzoni, R
Pommier, R
Raderer, M
Tomasek, J
Lahner, H
Valle, Juan W
Voi, M
Bubuteishvili-Pacaud, L
Lincy, J
Wolin, E
Okita, N
Libutti, S
Oh, D
Kulke, M
Strosberg, J
Yao, J
Pavel, M
Fazio, N
Affiliation
Sunnybrook Health Sciences Centre, Toronto, ONIssue Date
2018
Metadata
Show full item recordAbstract
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.Citation
Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. 2018, 106(3): 211-220 NeuroendocrinologyJournal
NeuroendocrinologyDOI
10.1159/000477585PubMed ID
28554173Type
ArticleLanguage
enISSN
1423-0194ae974a485f413a2113503eed53cd6c53
10.1159/000477585